PDA / BPC-157 Arginate
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
An arginate-salt analog of BPC-157 that appeared after BPC-157 was moved to FDA Category 2 in 2023, marketed as a more stable, more bioavailable version for tendon, tissue, and gut repair. It shares the same active pentadecapeptide sequence, but there are no peer-reviewed studies on the arginate form itself – vendors extrapolate entirely from BPC-157 acetate data, which is itself almost all animal work. It is currently one of the best-selling healing peptides despite this evidence gap, so its popularity far outruns what has actually been demonstrated in humans.
